Rapid disease progression after discontinuation of lenvatinib in thyroid cancer.
Yamazaki H, Sugino K, Matsuzu K, Masaki C, Akaishi J, Hames K, Tomoda C, Suzuki A, Uruno T, Ohkuwa K, Kitagawa W, Nagahama M, Masuda M, Ito K.
Yamazaki H, et al. Among authors: uruno t.
Medicine (Baltimore). 2020 Mar;99(11):e19408. doi: 10.1097/MD.0000000000019408.
Medicine (Baltimore). 2020.
PMID: 32176066
Free PMC article.